7 results about "Thrombo embolism" patented technology

A medical device is provided in which one or both ends of the device encourage the formation of tissue across substantially the entire area of the respective end that is exposed to the blood flow for reducing the risk of a thrombotic embolism. The medical device includes a tubular structure having at least one expanded volume portion and a tapered transition portion. The tubular structure may be made through the braiding of a number of strands, and a first end feature may be used to secure the proximal strand ends. The proximal strand ends may be secured via the proximal end of the first end feature, such that the tapered transition portion is formed over the circumferential surface of the first end feature, and only a proximal end surface (or a portion of the proximal end surface) of the first end feature is exposed to the path of flowing blood.

The present invention relates to novel sustained release formulation of milvexian, which are useful for the treatment or prevention of thromboembolic events. The invention is particularly suitable for once-a-day administration of milvexian, releasing a therapeutically effective amount of the milvexian over an extended time.

A computer-implemented system (CIS) is provided for processing and / or analyzing non-contrast-enhance computer tomography medical imaging input data is described. The CIS contains (i) twin U-Net architectures with equal weights, which are built on a Siamese architecture, and (ii) a Dissimilar block operably linked to the two U-Net architectures, and built on top of the Siamese-U-Net architecture to form a Dissimilar-Siamese-U-Net architecture. The computer-implemented system can be used in diagnosing acute ischemic stroke and / or thromoboembolus, by analyzing separate and independent input images of the left and right hemispheres of a brain. The diagnosis is based on a detection of the presence of a hyperdense middle cerebral artery sign.

This invention relates to the field of intelligent medical data analysis technology, specifically to a method and system for the intelligent prevention and control of venous thromboembolism in hospitalized patients. The method involves acquiring static medical record features and determining target test indicators; determining the target time window through a closed-loop adaptive mechanism driven by the fitting uncertainty of a Gaussian process regression model; constructing a weighted bipartite graph and removing confounding factors based on the topological overlap of pathological pathways to extract pure thrombosis baseline scores and pure bleeding baseline scores; extracting the first and second derivatives of time-series data and concatenating them with the pure baseline scores to construct a dynamic feature vector; generating a baseline-driven adaptive boundary in a two-dimensional phase plane; constructing a short-range predicted trajectory based on Taylor expansion and solving for the collision time; performing multi-objective game arbitration based on the time priority principle to generate prevention and control strategies; and achieving forward-looking joint decision-making in a dynamic conflicting scenario of thrombosis and bleeding risks.

The present invention provides a pharmaceutical composition containing ticagrelor for use in reducing or preventing thromboembolic events before and / or during and / or after neurovascular arterial procedures in a patient requiring the use of the pharmaceutical composition containing ticagrelor, comprising administering an effective amount of the pharmaceutical composition containing ticagrelor to a patient, wherein the pharmaceutical composition is an aqueous solution containing a solubilizing agent for ticagrelor and the pharmaceutical composition is administered intravenously; wherein the patient suffers from a cerebral aneurysm, cerebral arteriosclerosis, cervical arteriosclerosis, neurovascular carotid dissection or carotid dissection.